

AtriCure, Inc.  
Form 10-Q  
August 05, 2011  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 10-Q**

x **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

June 30, 2011 For the quarterly period ended June 30, 2011

or

.. **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from            to

Commission File Number 000-51470

**AtriCure, Inc.**

(Exact name of Registrant as specified in its charter)

Edgar Filing: AtriCure, Inc. - Form 10-Q

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**34-1940305**  
(I.R.S. Employer  
Identification No.)

**6217 Centre Park Drive**  
**West Chester, OH 45069**

(Address of principal executive offices)

**(513) 755-4100**

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: YES  NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES  NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer  Accelerated Filer   
Non-Accelerated Filer  (Do not check if a smaller reporting company) Smaller reporting company   
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): YES  NO

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class	Outstanding at July 31, 2011
Common Stock, \$.001 par value	16,264,491

**Table of Contents**

**Table of Contents**

	Page
PART I. FINANCIAL INFORMATION	
Item 1. <u>Financial Statements</u>	
<u>Condensed Consolidated Balance Sheets as of June 30, 2011 and December 31, 2010</u>	3
<u>Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2011 and 2010</u>	4
<u>Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2011 and 2010</u>	5
<u>Notes to Condensed Consolidated Financial Statements</u>	6
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	21
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	27
Item 4. <u>Controls and Procedures</u>	27
PART II. OTHER INFORMATION	
Item 1. <u>Legal Proceedings</u>	28
Item 1A. <u>Risk Factors</u>	28
Item 6. <u>Exhibits</u>	29
<u>Signatures</u>	30
<u>Exhibit Index</u>	31

**Table of Contents****PART I. FINANCIAL INFORMATION****Item 1. Financial Statements****ATRICURE, INC. AND SUBSIDIARY****CONDENSED CONSOLIDATED BALANCE SHEETS****(Unaudited)**

	<b>June 30, 2011</b>	<b>December 31, 2010</b>
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 4,111,921	\$ 4,230,709
Short-term investments	11,798,678	8,340,028
Accounts receivable, less allowance for doubtful accounts of \$26,340 and \$8,764, respectively	9,898,929	9,480,064
Inventories, net	6,009,527	5,680,033
Other current assets	1,227,510	2,917,571
Total current assets	33,046,565	30,648,405
Property and equipment, net	2,281,640	2,723,227
Intangible assets	55,625	89,375
Long-term investments	509,681	
Other assets	243,333	254,707
Total Assets	\$ 36,136,844	\$ 33,715,714
<b>Liabilities and Stockholders' Equity</b>		
Current liabilities:		
Accounts payable	\$ 5,184,660	\$ 4,511,516
Accrued liabilities	3,884,282	6,330,405
Current maturities of long-term debt and capital lease obligations	1,533,899	2,193,356
Total current liabilities	10,602,841	13,035,277
Long-term debt and capital lease obligations	5,670,042	661,624
Other liabilities	2,942,717	3,282,883
Total Liabilities	19,215,600	16,979,784
Commitments and contingencies (Note 7)		
Stockholders' Equity:		
Common stock, \$.001 par value, 90,000,000 shares authorized and 16,281,630 and 15,663,585 issued and outstanding, respectively	16,282	15,664
Additional paid-in capital	116,785,718	114,402,234
Accumulated other comprehensive income	100,536	79,625
Accumulated deficit	(99,981,292)	(97,761,593)
Total Stockholders' Equity	16,921,244	16,735,930
Total Liabilities and Stockholders' Equity	\$ 36,136,844	\$ 33,715,714

Edgar Filing: AtriCure, Inc. - Form 10-Q

See accompanying notes to condensed consolidated financial statements.

**Table of Contents**

**ATRICURE, INC. AND SUBSIDIARY**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

(Unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2011	2010	2011	2010
Revenue	\$ 16,779,563	\$ 14,192,312	\$ 32,416,644	\$ 28,144,112
Cost of revenue	4,502,085	2,963,673	8,246,362	6,236,309
Gross profit	12,277,478	11,228,639	24,170,282	21,907,803
Operating expenses:				
Research and development expenses	2,878,876	2,422,443	5,823,223	5,080,371
Selling, general and administrative expenses	10,169,771	9,239,056	20,192,423	18,950,578
Total operating expenses	13,048,647	11,661,499	26,015,646	24,030,949
Loss from operations	(771,169)	(432,860)	(1,845,364)	(2,123,146)
Other income (expense):				
Interest expense	(172,292)	(214,867)	(480,806)	(477,881)
Interest income	4,402	6,281	8,652	12,935
Other	1,614	(122,951)	111,525	(187,446)
Loss before income tax expense (benefit)	(937,445)	(764,397)	(2,205,993)	(2,775,538)
Income tax expense (benefit)	9,205	109	13,706	(1,681)
Net loss	\$ (946,650)	\$ (764,506)	\$ (2,219,699)	\$ (2,773,857)
Basic and diluted net loss per share	\$ (0.06)	\$ (0.05)	\$ (0.14)	\$ (0.18)
Weighted average shares outstanding basic and diluted	15,613,410	15,025,522	15,505,458	15,011,345

See accompanying notes to condensed consolidated financial statements.

**Table of Contents****ATRICURE, INC. AND SUBSIDIARY****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW****(Unaudited)**

	<b>Six Months Ended June 30,</b>	
	<b>2011</b>	<b>2010</b>
<b>Cash flows from operating activities:</b>		
Net loss	\$ (2,219,699)	\$ (2,773,857)
<b>Adjustments to reconcile net loss to net cash used in operating activities:</b>		
Share-based compensation expense	1,538,057	1,438,980
Depreciation	1,044,395	1,095,904
Write-off of deferred financing costs and discount on long-term debt	153,101	
Loss on disposal of equipment	45,481	
Amortization of deferred financing costs	46,962	51,500
Amortization of discount on long-term debt	21,707	102,602
Amortization of intangible assets	33,750	140,750
Change in allowance for doubtful accounts	17,576	(14,378)
<b>Changes in assets and liabilities:</b>		
Accounts receivable	(467,558)	(638,572)
Inventories	(268,930)	(1,247,449)
Other current assets	(253,612)	530,643
Accounts payable	658,152	247,703
Accrued liabilities	(792,900)	(595,912)
Other non-current assets and non-current liabilities	(60,383)	(222,084)
<b>Net cash used in operating activities</b>	<b>(503,901)</b>	<b>(1,884,170)</b>
<b>Cash flows from investing activities:</b>		
Purchases of property and equipment	(638,120)	(1,037,008)
Purchases of available-for-sale securities	(10,016,327)	(3,608,774)
Maturities of available-for-sale securities	6,050,000	5,298,491
Net proceeds from the sale of equipment	89,476	
<b>Net cash (used in) provided by investing activities</b>	<b>(4,514,971)</b>	<b>652,709</b>
<b>Cash flows from financing activities:</b>		
Payments on debt and capital leases	(3,278,274)	(1,113,078)
Proceeds from debt borrowings	7,500,000	
Payment of debt fees	(75,719)	(65,597)
Proceeds from issuance of common stock under employee stock purchase plan	345,852	225,084
Proceeds from stock option exercises	1,040,258	34,754
Shares repurchased for payment of taxes on stock awards	(522,528)	
<b>Net cash provided by (used in) financing activities</b>	<b>5,009,589</b>	<b>(918,837)</b>
Effect of exchange rate changes on cash and cash equivalents	(109,505)	98,979
<b>Net decrease in cash and cash equivalents</b>	<b>(118,788)</b>	<b>(2,051,319)</b>
Cash and cash equivalents beginning of period	4,230,709	8,905,425
<b>Cash and cash equivalents end of period</b>	<b>\$ 4,111,921</b>	<b>\$ 6,854,106</b>
<b>Supplemental cash flow information:</b>		
Cash paid for interest	\$ 167,044	\$ 236,939
Cash paid for taxes	\$ 17,780	\$ 21,639

Edgar Filing: AtriCure, Inc. - Form 10-Q

Non-cash investing and financing activities:

Purchases of property and equipment in current liabilities	\$	32,372	\$	36,630
Assets acquired through capital lease	\$	26,655	\$	

See accompanying notes to condensed consolidated financial statements.



---

**Table of Contents**

**ATRICURE, INC. AND SUBSIDIARY**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Unaudited)**

**1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Nature of the Business** AtriCure, Inc. (the Company or AtriCure) was incorporated in the State of Delaware on October 31, 2000. The Company develops, manufactures and sells devices designed primarily for the surgical ablation of cardiac tissue and devices for the exclusion of the left atrial appendage. The Company sells its products to hospitals and medical centers in the United States and internationally. International sales were \$4,117,811 and \$2,347,015 during the three months ended June 30, 2011 and 2010, respectively, and \$7,632,349 and \$5,248,641 during the six months ended June 30, 2011 and 2010, respectively.

**Basis of Presentation** The accompanying interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC). The accompanying interim financial statements are unaudited, but in the opinion of the Company's management, contain all of the normal, recurring adjustments considered necessary to present fairly the financial position, results of operations and cash flows for the periods presented in conformity with generally accepted accounting principles applicable to interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (GAAP) have been omitted or condensed. The Company believes the disclosures herein are adequate to make the information presented not misleading. Results of operations are not necessarily indicative of the results expected for the full fiscal year or for any future period.

The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the audited financial statements of the Company included in the Company's Annual Report on Form 10-K for the year ended December 31, 2010 filed with the SEC.

**Principles of Consolidation** The Condensed Consolidated Financial Statements include the accounts of the Company and AtriCure Europe, B.V., the Company's wholly-owned subsidiary incorporated in the Netherlands. All intercompany accounts and transactions have been eliminated in consolidation.

**Cash and Cash Equivalents** The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying Condensed Consolidated Financial Statements.

**Investments** The Company places its investments primarily in U.S. Government agencies and securities, corporate bonds and commercial paper. The Company classifies all investments as available-for-sale. Investments with maturities of less than one year are classified as short-term investments. Investments are recorded at fair value, with unrealized gains and losses recorded as a separate component of stockholders' equity. The Company recognizes gains and losses when these securities are sold using the specific identification method.

**Revenue Recognition** The Company accounts for revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 605, Revenue Recognition (ASC 605). The Company determines the timing of revenue recognition based upon factors such as passage of title, installation, payment terms and ability to return products. The Company recognizes revenue when all of the following criteria are met: (i) there is persuasive evidence that an arrangement exists; (ii) delivery of the products and/or services has occurred; (iii) the selling price is fixed or determinable; and (iv) collectability is reasonably assured.

Revenue is generated from the sale of the Company's surgical devices. The Company's surgical devices consist primarily of individual disposable handpieces and equipment generators. The Company's customers need the combination of the generator and the handpieces to have a functional system. The Company believes that the generator and handpiece are considered a single unit of accounting under ASC 605 because neither the generator nor handpiece have value to the customer on a standalone basis. Therefore, because the customer needs both the generator and handpiece to have a functional system, revenue is recognized upon the latter of delivery of the generator or the handpiece.

Pursuant to the Company's standard terms of sale, revenue is recognized when title to the goods and risk of loss transfers to customers and there are no remaining obligations that will affect the customer's final acceptance of the sale. Generally, the Company's standard terms of sale define the transfer of title and risk of loss to occur upon shipment to the respective customer. The Company generally does not maintain any post-shipment obligations to the recipients of the products. Typically, no installation, calibration or testing of this equipment is performed by the Company subsequent to shipment to the customer in order to render it operational.

## Edgar Filing: AtriCure, Inc. - Form 10-Q

Product revenue includes shipping and handling revenue of \$171,756 and \$167,454 for the three months ended June 30, 2011 and 2010, respectively, and \$345,764 and \$321,217 for the six months ended June 30, 2011 and 2010, respectively. Cost of freight for shipments made to customers is included in cost of revenue. Sales and other value-added taxes collected from customers and remitted

**Table of Contents****ATRICURE, INC. AND SUBSIDIARY****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Unaudited)**

to governmental authorities are excluded from revenue. The Company sells its products primarily through a direct sales force and through AtriCure Europe, B.V. Terms of sale are generally consistent for both end-users and distributors except that payment terms are generally net 30 days for end-users and net 60 days for distributors.

**Sales Returns and Allowances** The Company maintains a provision for sales returns and allowances to account for potential returns of defective or damaged products, products shipped in error, and price reductions given to customers. The Company estimates such provision quarterly based primarily on a specific identification basis. Increases to the provision result in a reduction of revenue.

**Allowance for Doubtful Accounts Receivable** The Company evaluates the collectability of accounts receivable in order to determine the appropriate reserve for doubtful accounts. In determining the amount of the reserve, the Company considers aging of account balances, historical credit losses, customer-specific information and other relevant factors. An increase to the allowance for doubtful accounts results in a corresponding increase in expense. The Company reviews accounts receivable and adjusts the allowance based on current circumstances and charges off uncollectible receivables against the allowance when all attempts to collect the receivable have failed.

**Inventories** Inventories are stated at the lower of cost or market using the first-in, first-out cost method ( FIFO ) and consist of raw materials, work in process and finished goods. A reserve for inventory is estimated and recorded for excess, slow moving and obsolete inventory as well as inventory with a carrying value in excess of its net realizable value. Write-offs are recorded when a product is destroyed. The Company reviews inventory on hand at least quarterly and records provisions for excess and obsolete inventory based on several factors including current assessment of future product demand, anticipated release of new products into the market, historical experience and product expiration. The Company's industry is characterized by rapid product development and frequent new product introductions. Uncertain timing of product approvals, variability in product launch strategies, and variation in product utilization all impact the estimates related to excess and obsolete inventory.

	<b>June 30, 2011</b>	<b>December 31, 2010</b>
Raw materials	\$ 2,965,172	\$ 2,583,030
Work in process	715,226	698,462
Finished goods	2,609,846	2,430,047
Reserve for obsolescence	(280,717)	(31,506)
<b>Inventories, net</b>	<b>\$ 6,009,527</b>	<b>\$ 5,680,033</b>

A business decision was made during the second quarter of 2011 to begin planning to discontinue the manufacturing of the Coolrail and Cryo1 devices. A reserve of \$250,000 for obsolete inventory was recorded as a result of this decision.

**Property and Equipment** Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method of depreciation for financial reporting purposes and applied over the estimated useful lives of the assets. The estimated useful life by major asset category is the following: machinery and equipment is three to seven years, computer and other office equipment is three years, furniture and fixtures is three to seven years, and leasehold improvements and equipment leased under a capital lease are the shorter of their useful life or remaining lease term. Maintenance and repair costs are expensed as incurred.

Included in property and equipment are generators and other capital equipment (such as the Company's switchbox units and cryosurgical consoles) that are loaned at no cost to direct customers that use the Company's disposable products. These generators are depreciated over a period of one to three years, which approximates their useful lives, and such depreciation is included in cost of revenue. The estimated useful lives of this equipment are based on anticipated usage by our customers and the timing and impact of expected new technology rollouts by the Company. To the extent the Company experiences changes in the usage of this equipment or introductions of new technologies, the estimated

## Edgar Filing: AtriCure, Inc. - Form 10-Q

useful lives of this equipment may change in a future period. Depreciation related to these generators was \$390,773 and \$318,137 for the three months ended June 30, 2011 and 2010, respectively, and \$757,580 and \$645,513 for the six months ended June 30, 2011 and 2010, respectively. As of June 30, 2011 and December 31, 2010, the net carrying amount of loaned equipment included in net property and equipment in the Condensed Consolidated Balance Sheets was \$1,308,657 and \$1,630,163, respectively.

***Impairment of Long-Lived Assets*** The Company reviews property and equipment and definite-lived intangibles for impairment using its best estimates based on reasonable and supportable assumptions and projections in accordance with FASB ASC 360, Property, Plant and Equipment (ASC 360). The Company recorded a charge within cost of revenue of \$1,031 during the six months ended June 30, 2011 for the impairment of machinery and equipment related to the planned discontinuance of a product. The Company did not recognize any impairment of long-lived assets for the six months ended June 30, 2010.

**Table of Contents****ATRICURE, INC. AND SUBSIDIARY****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Unaudited)**

**Intangible Assets** Intangible assets with determinable useful lives are amortized on a straight-line basis over the estimated periods benefited, which range from four to eight years.

**Grant Income** The Company receives research grants, which are recognized as funds are expended and not as awarded by awarding agencies.

**Income Taxes** Income taxes are computed using the asset and liability method in accordance with FASB ASC 740 Income Taxes (ASC 740), under which deferred income taxes are provided for the temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities. Deferred taxes are measured using provisions of currently enacted tax laws. A valuation allowance against deferred tax assets is recorded when it is more likely than not that such assets will not be fully realized. Tax credits are accounted for as a reduction of income taxes in the year in which the credit originates.

The Company's estimate of the valuation allowance for deferred tax assets requires it to make significant estimates and judgments about its future operating results. The Company's ability to realize the deferred tax assets depends on its future taxable income as well as limitations on their utilization. A deferred tax asset is reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized prior to its expiration. The projections of the Company's operating results on which the establishment of a valuation allowance is based involve significant estimates regarding future demand for the Company's products, competitive conditions, product development efforts, approvals of regulatory agencies and product cost. If actual results differ from these projections, or if the Company's expectations of future results change, it may be necessary to adjust the valuation allowance.

**Net Loss Per Share** Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Since the Company has experienced net losses for all periods presented, net loss per share excludes the effect of 3,191,028 and 3,584,753 options, restricted stock and performance based shares as of June 30, 2011 and 2010, respectively, because they are anti-dilutive. Therefore the number of shares calculated for basic net loss per share is also used for the diluted net loss per share calculation.

**Comprehensive Loss and Accumulated Other Comprehensive Income** In addition to net losses, the comprehensive loss includes foreign currency exchange rate adjustments and unrealized gains and losses on investments. The comprehensive loss for the three and six months ended June 30, 2011 was \$941,312 and \$2,198,788, respectively. The comprehensive loss for the three and six months ended June 30, 2010 was \$924,972 and \$3,025,212, respectively.

Accumulated other comprehensive income consisted of the following:

	Unrealized Gains (Losses) on Short-Term Investments	Foreign Currency Translation Adjustment	Accumulated Other Comprehensive Income
Balance as of December 31, 2010	\$ (321)	\$ 79,946	\$ 79,625
January 1, 2011 to March 31, 2011 change	2,332	13,242	15,574
Balance as of March 31, 2011	2,011	93,188	95,199
April 1, 2011 to June 30, 2011 change	(292)	5,629	5,337
Balance as of June 30, 2011	\$ 1,719	\$ 98,817	\$ 100,536

**Foreign Currency Transaction Gains (Losses)** The Company recorded foreign currency transaction gains (losses) of \$40,257 and (\$95,746) for the three months ended June 30, 2011 and 2010, respectively, and \$136,288 and (\$159,952) for the six months ended June 30, 2011 and 2010,

## Edgar Filing: AtriCure, Inc. - Form 10-Q

respectively, in connection with partial settlements of its intercompany balance with its subsidiary.

**Research and Development** Research and development costs are expensed as incurred. These costs include compensation and other internal and external costs associated with the development and research related to new products or concepts, preclinical studies, clinical trials and the cost of products used in trials and tests.

**Share-Based Compensation** The Company follows FASB ASC 718 Compensation-Stock Compensation ( ASC 718 ), to record share-based compensation for all share-based payment awards, including stock options, restricted stock, performance shares and employee stock purchases related to an employee stock purchase plan, based on estimated fair values. The Company's share-based compensation expense recognized under ASC 718 for the three months ended June 30, 2011 and 2010 was \$734,650 and \$626,946 respectively, and \$1,538,057 and \$1,438,980 for the six months ended June 30, 2011 and 2010, respectively, on a before and after tax basis.

---

**Table of Contents**

**ATRICURE, INC. AND SUBSIDIARY**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Unaudited)**

FASB ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company's Condensed Consolidated Statement of Operations. The expense has been reduced for estimated forfeitures. FASB ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

The Company estimates the fair value of options on the date of grant using the Black-Scholes option-pricing model ( Black-Scholes model ). The Company's determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by the Company's stock price, as well as assumptions regarding a number of highly complex and subjective variables. These variables include but are not limited to the Company's and the peer group's expected stock price volatility over the term of the awards and actual and projected employee stock option exercise behaviors. For non-employee options, the fair value at the date of grant is subject to adjustment at each vesting date based upon the fair value of the Company's common stock.

The Company estimates the fair value of restricted stock and performance share awards based upon the grant date closing market price of the Company's common stock. The Company's determination of fair value is affected by the Company's stock price as well as assumptions regarding the number of shares expected to be granted and, in the case of performance shares, the likelihood that the performance measures will be achieved.

The Company also has an employee stock purchase plan ( ESPP or the Plan ) which is available to all eligible employees as defined by the Plan. Under the ESPP, shares of the Company's common stock may be purchased at a discount. The Company estimates the number of shares to be purchased under the Plan and records compensation expense based upon the fair value of the stock at the beginning of the purchase period using the Black-Scholes model.

The Company has historically issued stock options to non-employee consultants as a form of compensation for services provided to the Company. The Company accounts for the options granted to non-employees prior to their vesting date in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Because these options do not contain specific performance provisions, there is no measurement date of fair value until the options vest. Therefore, the fair value of the options granted and outstanding prior to their vesting date is remeasured each reporting period. During the three months ended June 30, 2011 and 2010, \$4,535 and \$3,295, respectively, of compensation expense was recorded as a result of the remeasurement of the fair value of these unvested stock options. During the six months ended June 30, 2011 and 2010, \$10,704 and \$6,161, respectively, of expense was recorded as a result of the remeasurement of the fair value of these unvested stock options.

Because the options require settlement by the Company's delivery of registered shares and because the tax withholding provisions in the awards allow the options to be partially net-cash settled, these options, when vested, are no longer eligible for equity classification and are, thus, subsequently accounted for as derivative liabilities under FASB ASC 815 until the awards are ultimately either exercised or forfeited. Accordingly, the vested non-employee options are classified as liabilities and remeasured at fair value through earnings at each reporting period.

During the three months ended June 30, 2011 and 2010, expense of \$42,703 and \$27,204, respectively, was recorded as a result of the remeasurement of the fair value of these fully vested stock options. During the six months ended June 30, 2011 and 2010, \$48,974 and \$27,494, respectively, of expense was recorded as a result of the remeasurement of the fair value of these fully vested stock options. Fully vested options to acquire 39,603 and 41,049 shares of common stock held by non-employee consultants remained unexercised as of June 30, 2011 and December 31, 2010, respectively. A liability of \$334,990 and \$268,478 was included in accrued liabilities in the Condensed Consolidated Balance Sheets as of June 30, 2011 and December 31, 2010, respectively.

**Use of Estimates** The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates.

**Fair Value Disclosures** The book value of the Company's financial instruments, including cash and cash equivalents, accounts receivable, short-term investments, short and long-term other assets, accounts payable, accrued expenses, other liabilities and fixed interest rate debt,

approximate their fair values.

## **2. RECENT ACCOUNTING PRONOUNCEMENTS**

In October 2009, the FASB issued new guidance in ASC 985, Software, which amends the accounting and disclosure for revenue recognition. These amendments, effective for fiscal years beginning on or after June 15, 2010 (early adoption is permitted), modify the criteria for recognizing revenue in multiple element arrangements and the scope of what constitutes a non-software deliverable. The Company has evaluated the provisions of ASC 985 and has determined that it does not have a material impact on its consolidated financial position and results of operations.



**Table of Contents****ATRICURE, INC. AND SUBSIDIARY****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Unaudited)**

In January 2010, the FASB issued new guidance in ASC 820, Fair Value Measurements and Disclosures, which requires reporting entities to make new disclosures about recurring or nonrecurring fair value measurements including (i) significant transfers into and out of Level 1 and Level 2 fair value measurements and (ii) information on purchases, sales, issuances and settlements on a gross basis in the reconciliation of Level 3 fair value measurements. This new guidance is effective for interim and annual reporting periods beginning after December 15, 2009, except for Level 3 reconciliation disclosures, which are effective for interim and annual periods beginning after December 15, 2010. The Company has incorporated the additional disclosures required for fair value measurements.

In June 2011, the FASB issued new guidance in ASU 2011-05, Presentation of Comprehensive Income, which revises the manner in which entities present comprehensive income in their financial statements. This new guidance requires entities to report components of comprehensive income in either (1) a continuous statement of comprehensive income or (2) two separate but consecutive statements. It is effective for interim and annual reporting periods beginning after December 15, 2011. The Company is in the process of evaluating the impact of this ASU on its financial reporting.

**3. FAIR VALUE**

FASB ASC 820, Fair Value Measurements and Disclosures (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

Level 1 Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. The valuation under this approach does not entail a significant degree of judgment.

Level 2 Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The valuation technique for the Company's Level 2 assets is based on quoted market prices for similar assets from observable pricing sources at the reporting date.

Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. The fair value of the Company's Level 3 investments are estimated on the grant date using the Black-Scholes model and they are revalued at the end of each reporting period using the Black-Scholes model.

In accordance with ASC 820, the following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2011:

Quoted Prices in Active Markets for	Significant Other	Significant Other Unobservable	Total
--	----------------------	-----------------------------------	-------

Edgar Filing: AtriCure, Inc. - Form 10-Q

	Identical Assets (Level 1)	Observable Inputs (Level 2)	Inputs (Level 3)	
<b>Assets:</b>				
Money market funds	\$	\$ 2,517,035	\$	\$ 2,517,035
Commercial paper		5,195,162		5,195,162
U.S. government agencies and securities	5,172,323			5,172,323
Corporate bonds		1,940,874		1,940,874
Total assets	\$ 5,172,323	\$ 9,653,071	\$	\$ 14,825,394
<b>Liabilities:</b>				
Derivative instruments	\$	\$	\$ 334,990	\$ 334,990
Total liabilities	\$	\$	\$ 334,990	\$ 334,990

**Table of Contents****ATRICURE, INC. AND SUBSIDIARY****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Unaudited)**

In accordance with ASC 820, the following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2010:

	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Other Unobservable Inputs (Level 3)	Total
<b>Assets:</b>				
Money market funds	\$	\$ 1,222,618	\$	\$ 1,222,618
Commercial paper		2,399,038		2,399,038
U.S. government agencies and securities	5,836,594			5,836,594
Corporate bonds	704,207			704,207
Total assets	\$ 6,540,801	\$ 3,621,656	\$	\$ 10,162,457
<b>Liabilities:</b>				
Derivative instruments	\$	\$	\$ 268,478	\$ 268,478
Total liabilities	\$	\$	\$ 268,478	\$ 268,478

The fair value of the Level 3 liabilities is estimated using the Black-Scholes model including the following assumptions:

	As of June 30, 2011		As of December 31, 2010	
Risk free interest rate	0.31%	1.99%	0.12%	1.86%
Expected life of option (years)	1.48	5.62	0.16	4.71
Expected volatility of stock	70.00%		65.00%	
Dividend yield	0.00%		0.00%	

The Company has historically issued stock options to non-employee consultants as a form of compensation for services provided to the Company. Once these non-employee options have vested, the awards no longer fall within the scope of ASC 505-50. Because the options require settlement by the Company's delivery of registered shares and because the tax withholding provisions in the awards allow the options to be partially net-cash settled, these vested options are no longer eligible for equity classification and are, thus, accounted for as derivative liabilities under FASB ASC 815 ( Derivatives and Hedging ) until the awards are ultimately either exercised or forfeited. Accordingly, the vested non-employee options are classified as liabilities and remeasured at fair value through earnings at each reporting period. In calculating the fair value of the options, they are estimated on the grant date using the Black-Scholes model subject to change in stock price utilizing assumptions of risk-free interest rate, contractual life of option, expected volatility, weighted average volatility and dividend yield. Due to the lack of certain observable market quotes, the Company utilizes valuation models that rely on some Level 3 inputs. Specifically, before December 31, 2010, the Company's estimate of volatility was weighted 75% and 25% between the Company's implied volatility and the implied volatility of a group of comparable companies, respectively. Beginning January 1, 2011, the Company's estimate of volatility is based solely on the Company's trading history. In accordance with ASC 820, the following table represents the company's Level 3 fair value measurements using significant other unobservable inputs for derivative instruments as of June 30, 2011:

Edgar Filing: AtriCure, Inc. - Form 10-Q

Beginning Balance	\$ 268,478
Total losses (realized/unrealized) included in earnings	48,974
Purchases	
Issuances	17,538
Settlements	
Ending Balance	\$ 334,990
Losses included in earnings (or changes in net assets attributable to the change in unrealized losses relating to assets held at reporting date)	\$ (48,974)

**Table of Contents****ATRICURE, INC. AND SUBSIDIARY****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Unaudited)**

In accordance with ASC 820, the following table represents the company's Level 3 fair value measurements using significant other unobservable inputs for derivative instruments as of December 31, 2010:

Beginning Balance	\$ 180,288
Total losses (realized/unrealized) included in earnings	164,959
Purchases, issuances and settlements	(76,769)
Ending Balance	\$ 268,478
Losses included in earnings (or changes in net assets attributable to the change in unrealized losses relating to assets held at reporting date)	\$ (164,959)

**4. INTANGIBLE ASSETS**

Intangible assets with definite lives are amortized over their estimated useful lives. The following table provides a summary of the Company's intangible assets with definite lives:

	<b>Proprietary Manufacturing Technology</b>	<b>Non-Compete Agreement</b>	<b>Trade Name</b>	<b>Total</b>
Net carrying amount as of December 31, 2009	\$ 130,778	\$ 69,792	\$ 87,083	\$ 287,653
Amortization	(130,778)	(12,500)	(55,000)	(198,278)
Net carrying amount as of December 31, 2010		57,292	32,083	89,375
Amortization		(6,250)	(27,500)	(33,750)
Net carrying amount as of June 30, 2011	\$	\$ 51,042	\$ 4,583	\$ 55,625

Amortizable intangible assets are being amortized over eight years for a non-compete arrangement, four years for trade name usage and five years for proprietary manufacturing technology. Amortization expense related to intangible assets with definite lives was \$16,875 and \$70,375 for the three months ended June 30, 2011 and 2010, respectively, and \$33,750 and \$140,750 for the six months ended June 30, 2011 and 2010, respectively.

Estimated future amortization expense related to intangible assets with definite lives is as follows:

<b>Year</b>	<b>Amortization</b>	
2011	\$ 10,833	July 1, 2011 through December 31, 2011
2012	12,500	
2013	12,500	

Edgar Filing: AtriCure, Inc. - Form 10-Q

2014	12,500
2015	7,292
Total	\$ 55,625

**5. ACCRUED LIABILITIES**

Accrued liabilities consisted of the following:

	<b>June 30, 2011</b>	<b>December 31, 2010</b>
Accrued commissions	\$ 932,965	\$ 1,178,854
Accrued taxes	687,593	435,495
Accrued DOJ settlement reserve (current portion)	569,327	486,975
Other accrued liabilities	475,009	671,477
Accrued bonus	471,479	894,492
Accrued non-employee stock options	334,990	268,478
Accrued vacation	250,487	257,235
Accrued payroll	162,432	137,399
Accrued class action settlement reserve		2,000,000
Total	\$ 3,884,282	\$ 6,330,405

**Table of Contents****ATRICURE, INC. AND SUBSIDIARY****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Unaudited)****6. INDEBTEDNESS**

On May 1, 2009, the Company and Silicon Valley Bank ( SVB ) entered into a Loan and Security Agreement (the Agreement ) that provided for a term loan and a revolving credit facility under which the Company could borrow a maximum of \$10,000,000. The Company could borrow up to \$10,000,000 under the revolving loan facility with the availability subject to a borrowing base formula. On May 1, 2009, the Company borrowed the maximum amount of \$6,500,000 under the term loan. In connection with the term loan, SVB received a warrant to purchase 371,732 shares of the Company s common stock at \$1.224 per share, exercisable for a term of ten years (the Warrant ). The Warrant was immediately exercisable and was exercised via a net share settlement exercise on October 6, 2009, resulting in the issuance of 276,143 shares of the Company s common stock. Upon issuance of the term loan and the Warrant, the Company allocated the related proceeds between these two financial instruments based on their relative fair values in accordance with FASB ASC 470, Debt. Proceeds of \$455,000 were allocated to the Warrant and recorded as additional paid-in-capital, and the remaining proceeds of \$6,045,003 were recorded as the initial net carrying value of the debt. The Agreement also included up to a \$1,000,000 sublimit for stand-by letters of credit.

On November 4, 2009, effective September 30, 2009, the Company entered into a Consent, Waiver and First Loan Modification Agreement with SVB, which amended, among other things, the financial covenants in the Agreement. On March 26, 2010, the Company entered into a Waiver and Second Loan Modification Agreement with SVB, which amended, among other things, the financial covenants in the Agreement and waived a compliance violation which occurred during February 2010.

On September 13, 2010, the Company entered into an Amended and Restated Loan and Security Agreement with SVB and an Export-Import Bank Loan and Security Agreement. This amendment increased the Company s credit facility from \$10,000,000 to approximately \$14,000,000. The amendment also increased the Company s borrowing capacity under the revolving loan facility by expanding total availability, eliminating a term loan reserve requirement, adding a sublimit secured by certain of the Company s foreign accounts receivable and inventory up to \$2,000,000 and adding incremental borrowing availability secured by a portion of the Company s domestic inventory. Interest on the term loan portion accrued at a rate of 10.0% per year, and interest on the revolving loan would accrue at a fluctuating rate equal to SVB s announced prime rate of interest, subject to a floor of 4.0%, plus between 1.0% and 2.0%, depending on the Company s Adjusted Quick Ratio (as defined in the Agreement). Principal on the term loan was being paid over 36 months in equal principal payments of \$180,556 plus applicable interest. The Agreement was to mature on April 30, 2012 and was secured by all of the Company s assets, including intellectual property.

On March 15, 2011, the Company and SVB entered into a First Loan Modification Agreement (the Loan Modification Agreement ) and an Export-Import Bank First Loan Modification Agreement (the Ex-Im Agreement and, collectively with the Loan Modification Agreement, the Modification Agreements ) which set forth certain amendments to the Company s credit facility with SVB. The Loan Modification Agreement provided for a new \$7,500,000 term loan. The proceeds from the term loan were used to repay the amount outstanding under the existing SVB term loan of \$2,500,000. The balance was invested in short-term investments. The new term loan has a five-year term, and principal payments in the amount of \$125,000, together with accrued interest, are due and payable monthly. The modified term loan accrues interest at a fixed rate of 6.75%.

The Modification Agreements also provide for a two-year extension of the maturity date of the existing revolving credit facility from April 30, 2012 to April 30, 2014. The applicable borrowing rate was reduced to 0.25% to 0.75% above the prime rate. The maximum borrowing amount under the revolving facility remained at \$10,000,000.

The Agreement, as amended, contains covenants that include, among others, covenants that limit the Company s and its subsidiaries ability to dispose of assets, enter into mergers or acquisitions, incur indebtedness, incur liens, pay dividends or make distributions on the Company s capital stock, make investments or loans, and enter into certain affiliate transactions, in each case subject to customary exceptions for a credit facility of this size and type. Additional covenants apply when the Company has outstanding borrowings under the revolving loan facility or when the Company achieves specific covenant milestones. Financial covenants under the credit facility, as amended, include a minimum EBITDA, a limitation on capital expenditures, and a minimum adjusted quick ratio. Further, a minimum fixed charge ratio applies when the Company achieves specific covenant milestones. The occurrence of an event of default could result in an increase to the applicable interest rate by 3.0%, an acceleration of all obligations under the Agreement, an obligation of the Company to repay all obligations in full, and a right by

## Edgar Filing: AtriCure, Inc. - Form 10-Q

SVB to exercise all remedies available to it under the Agreement and related agreements including the Guaranty and Security Agreement. As of and for the period ended June 30, 2011, the Company was in compliance with all of the financial covenants of the amended and modified credit facility. In addition, if the guarantee by the Export-Import Bank of the United States ceases to be in full force and effect, the Company must repay all loans under the Export-Import agreement.



**Table of Contents****ATRICURE, INC. AND SUBSIDIARY****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Unaudited)**

As of June 30, 2011, the Company had no borrowings under the revolving credit facility and had borrowing availability of approximately \$8,200,000. Also, as of June 30, 2011, \$7,125,000 was outstanding under the term loan, which included \$1,500,000 classified as current maturities of long-term debt.

The Warrant that was issued with the initial SVB Agreement had been recorded as a discount on long-term debt at its fair value and was being amortized over the term of the loan. Accelerated amortization expense of \$78,873 was recorded in March 2011 due to the credit facility modification. No amortization expense related to the Warrant was recorded for the three months ended June 30, 2011.

In addition to the accelerated amortization of the Warrant, the Company also recorded \$74,228 of expense related to deferred financing costs and other fees as a result of the credit facility modification in March 2011.

The effective interest rate on borrowings under the modified term loan, including debt issuance costs, is 8.0%. On June 20, 2011, the Company cancelled an outstanding letter of credit of \$250,000 issued to its corporate credit card program provider which was to expire on July 31, 2011.

As of June 30, 2011, the Company had capital leases for computer and office equipment that expire at various terms through 2015, and the cost of the assets under lease was \$234,503. These assets are depreciated over the estimated useful lives of the assets, which equal the term of the lease. Accumulated amortization on the capital leases was \$150,200 at June 30, 2011.

Maturities on long-term debt, including capital lease obligations, are as follows:

2011	\$ 766,528	July 1, 2011 through December 31, 2011
2012	1,535,630	
2013	1,517,288	
2014	1,507,501	
2015	1,501,995	
2016	375,000	
<b>Total maturities on long-term debt</b>	<b>\$ 7,203,941</b>	

As of December 31, 2010, the Company had no borrowings under its revolving credit facility and borrowing availability of \$8,136,523. Also as of December 31, 2010, the Company had \$2,888,889 outstanding under its term loan, which included \$2,166,667 classified as current maturities of long-term debt. As of December 31, 2010, the Company had an outstanding letter of credit of \$250,000 issued to its corporate credit card program provider. This letter of credit was cancelled in June 2011, and no letters of credit were outstanding at June 30, 2011.

**7. COMMITMENTS AND CONTINGENCIES*****Operating Leases***

The Company leases various types of office, manufacturing and warehouse facilities and equipment under noncancelable operating leases that expire at various terms through 2014.

***Royalty Agreements***

## Edgar Filing: AtriCure, Inc. - Form 10-Q

The Company has certain royalty agreements in place with terms that include payment of royalties based on product revenue from sales of current products. One royalty agreement, which was effective January 1, 2010, has a rate of 1.5% of product sales and includes minimum quarterly payments of \$50,000 through 2015 and a maximum of \$2,000,000 in total royalties over the term of the agreement. Another royalty agreement, which was effective in 2003 and has a term of at least twenty years, has royalty rates of 5% of product sales. Parties to the royalty agreements have the right at any time to terminate the agreement immediately for cause. Royalty expense of \$128,900 and \$57,890 was recorded as part of cost of revenue for the three months ended June 30, 2011 and 2010, respectively, and \$256,550 and \$110,048 for the six months ended June 30, 2011 and 2010, respectively.

### *Purchase Agreement*

On June 15, 2007, the Company entered into a purchase agreement with MicroPace Pty Ltd Inc. ( MicroPace ). The agreement, as amended, provides for MicroPace to produce a derivative of one of their products tailored for the cardiac surgical environment, known as the MicroPace ORLab for worldwide distribution by the Company. Pursuant to the terms of the amended agreement, in order for the Company to retain exclusive distribution rights, the Company is required to purchase a minimum of 40 units during the

---

**Table of Contents**

**ATRICURE, INC. AND SUBSIDIARY**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Unaudited)**

period December 1, 2010 through December 31, 2011 to extend exclusivity through 2012 and an additional 40 units during 2012 to extend exclusivity through December 31, 2013. A total of 41 units were purchased by the Company between December 1, 2010 and June 30, 2011, thereby extending exclusive distribution rights through December 31, 2012. Units purchased in excess of yearly minimums reduce future minimum purchase requirements.

***Life Support Technology, LST b.v.***

In September 2007, multiple proceedings between the Company and Life Support Technology ( LST b.v. or LST ), a former distributor of AtriCure products in Europe, were settled. The settlement agreement provided for the Company to pay LST 257,360 (Euros) in 16 payments of 16,085, with the final payment made in January 2011.

***Distributor Termination***

On July 2, 2010, the Company terminated a distributor agreement with a European distributor. Under the terms of the agreement the Company paid the distributor 200,000 (approximately \$256,000), repurchased saleable disposable product inventory for 107,196 (approximately \$137,000), and paid 75,000 (approximately \$96,000) for capital equipment. Additionally, the Company entered into a consulting agreement with the distributor to provide ongoing consulting services through September 30, 2012. In exchange for these services, beginning October 1, 2010, the distributor will earn 50,000 (approximately \$70,000) per quarter for a total of 400,000 (approximately \$560,000). Additionally, the distributor earned 10,000 (approximately \$14,000) per month for consulting services during the third quarter of 2010.

**Legal**

**Class Action Lawsuits**

AtriCure, Inc. and certain of its current and former officers were named as defendants in a purported securities class action lawsuit filed in the United States District Court for the Southern District of New York (Levine v. AtriCure, Inc., Case No. 06 CV 14324 (United States District Court for the Southern District of New York)). The suit alleges violations of the federal securities laws and seeks damages on behalf of purchasers of the Company's common stock during the period from our initial public offering in August 2005 through February 16, 2006. The Company filed a motion to dismiss the lawsuit for lack of subject matter jurisdiction. This motion was denied in September 2007, and a motion for reconsideration of that denial was denied in January 2009. Although the Company admitted no wrongdoing, as of December 31, 2009, the Company recorded a liability of \$2,000,000 which represented an estimate of the potential defense and/or settlement costs. In addition, the Company recorded a related receivable of \$2,000,000 from its insurance carrier for the potential defense and/or settlement costs, as recovery was expected beyond a reasonable doubt. On October 22, 2010, the parties signed a Definitive Stipulation of Settlement for \$2,000,000, which was subject to notice to the class as well as approval by the court, which occurred on May 27, 2011. The Company's insurance carrier paid the claim in full in June 2011, and, as of June 30, 2011, no receivables or liabilities existed in relation to this matter.

On December 12, 2008, AtriCure, Inc. and certain of its current executive officers were named in a putative class action lawsuit which is now captioned In re AtriCure, Inc. Securities Litigation, filed in the U.S. District Court for the Southern District of Ohio, Western Division. The plaintiffs allege violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder and seek unspecified damages against AtriCure, Inc. and certain of its current executive officers. The plaintiffs allege, among other things, that the defendants issued materially false and misleading statements that failed to disclose that the Company improperly promoted certain products to physicians and caused the filing of false claims for reimbursement. The class period alleged ran from May 10, 2007 through October 31, 2008. In July 2009 the Company filed a motion to dismiss, and in September 2009, the plaintiffs filed their memorandum in opposition to the Company's motion to dismiss to which the Company responded on November 9, 2009. On March 29, 2010, the court granted, in part, and denied, in part, the Company's motion to dismiss and, in particular, dismissed the claim that the Company caused the filing of false claims for reimbursement. On October 7, 2010, the court ordered final approval of the settlement for \$2,750,000 which was funded by the Company's insurance carrier.

**Department of Justice Investigation**

On October 27, 2008, the Company received a letter from the Department of Justice ( DOJ ) informing the Company that the DOJ was conducting an investigation for potential False Claims Act ( FCA ) and common law violations relating to its surgical ablation devices. Specifically, the letter stated that the DOJ was investigating the Company s marketing practices utilized in connection with its surgical ablation system to treat atrial fibrillation ( AF ), a specific use outside the FDA s 510(k) clearance. The letter also stated that the DOJ was investigating whether the Company instructed hospitals to bill Medicare for cardiac surgical ablation using incorrect billing codes. The Company cooperated with the investigation and operated its business in the ordinary course

---

**Table of Contents**

**ATRICURE, INC. AND SUBSIDIARY**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Unaudited)**

during the investigation. As of December 31, 2009, the Company reached a tentative settlement with the DOJ to resolve the investigation and recorded a liability and charged operating expenses for a total of \$3,955,405 which represented the net present value of the proposed settlement amount to be paid to the DOJ, the Relator, and Relator's counsel (total payments based on the settlement inclusive of interest were estimated to be \$4,350,000, payable over five years).

On February 2, 2010, the settlement was finalized pursuant to the preliminary terms and the Company entered into a settlement agreement with the DOJ, the Office of the Inspector General (OIG) and the Relator in the *qui tam* complaint discussed below. The settlement agreement definitively resolved all claims related to the DOJ investigation. The Company did not admit nor will it admit to any wrongdoing in connection with the settlement. As of June 30, 2011, the Company had made \$950,000 in payments (including interest), and has a liability related to this settlement totaling \$3,197,660, of which \$569,327 is classified as current.

As part of the resolution, the Company also entered into a five year Corporate Integrity Agreement with the OIG. This agreement acknowledges the existence of the Company's corporate compliance program and provides for certain other compliance-related activities during the five year term of the agreement. Those activities include specific written standards, monitoring, training, education, independent review, disclosure and reporting requirements.

***Qui Tam* Complaint**

On July 10, 2009, a copy of a *qui tam* complaint against the Company was unsealed. The *qui tam* complaint, filed in the U.S. District Court for the Southern District of Texas, was originally filed by the Relator in August 2007. The complaint, which was related to the DOJ investigation, alleged a cause of action under the FCA relating to the Company's alleged marketing practices in connection with its surgical cardiac ablation devices. In August 2009 the DOJ declined to intervene in the *qui tam* complaint. The *qui tam* complaint was settled in February 2010 in accordance with the DOJ settlement agreement.

The Company may from time to time become a party to additional legal proceedings.

**8. INCOME TAX PROVISION**

The Company files federal, state, and foreign income tax returns in jurisdictions with varying statutes of limitations. Income taxes are computed using the asset and liability method in accordance with FASB ASC 740 under which deferred income taxes are provided for the temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities. Deferred taxes are measured using provisions of currently enacted tax laws. A valuation allowance against deferred tax assets is recorded when it is more likely than not that such assets will not be fully realized. Tax credits are accounted for as a reduction of income taxes in the year in which the credit originates. The Company does not expect any significant unrecognized tax benefits to arise over the next twelve months.

The Company's provision for income taxes for continuing operations in interim periods is computed by applying its estimated annual effective rate against its loss before income tax (expense) benefit for the period. In addition, non-recurring or discrete items are recorded during the period in which they occur. The effective tax rate for the three months ended June 30, 2011 and 2010 was (0.98%) and (0.01%), respectively. The effective tax rate for the six months ended June 30, 2011 and 2010 was (0.62%) and 0.06%, respectively.

The Company currently has not had to accrue interest and penalties related to unrecognized income tax benefits. However, when or if the situation occurs, the Company will recognize interest and penalties within the income tax expense (benefit) line in the accompanying Condensed Consolidated Statements of Operations and within the related tax liability in the Condensed Consolidated Balance Sheets.

**9. EQUITY COMPENSATION PLANS**

## Edgar Filing: AtriCure, Inc. - Form 10-Q

The Company has several share-based incentive plans: the 2001 Stock Option Plan (the 2001 Plan ), the 2005 Equity Incentive Plan (the 2005 Plan ) and the 2008 Employee Stock Purchase Plan (the ESPP ).

### ***2001 Plan and 2005 Plan***

The 2001 Plan is no longer used for granting incentives. Under the 2005 Plan, the Board of Directors may grant incentive stock options to employees and any parent or subsidiary s employees, and may grant nonstatutory stock options, restricted stock, stock appreciation rights, performance units or performance shares to employees, directors and consultants of the Company and any parent or subsidiary s employees, directors and consultants. The administrator (currently the Compensation Committee of the Board of Directors) has the power to determine the terms of any awards, including the exercise price of options, the number of shares subject to each award, the exercisability of the awards and the form of consideration.

**Table of Contents****ATRICURE, INC. AND SUBSIDIARY****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Unaudited)**

Options granted under the 2001 Plan and the 2005 Plan generally expire ten years from the date of grant. Options granted from the 2001 Plan are generally exercisable beginning one year from the date of grant in cumulative yearly amounts of 25% of the shares granted. Options granted from the 2005 Plan generally vest over four years at a rate of 25% on the first anniversary date of the grant and ratably each month thereafter. Certain options granted were exercisable at the time of the grant and the underlying unvested shares are subject to the Company's repurchase rights as stated in the applicable plan agreement.

As of June 30, 2011, 5,812,198 shares of common stock had been reserved for issuance under the 2005 Plan. The shares authorized for issuance under the 2005 Plan include: (a) shares reserved but unissued under the 2001 Plan as of August 10, 2005, (b) shares returned to the 2001 Plan as the result of termination of options or the repurchase of shares issued under such plan, and (c) annual increases in the number of shares available for issuance on the first day of each year equal to the lesser of:

3.25% of the outstanding shares of common stock on the first day of the fiscal year;

825,000 shares; or

an amount the Company's Board of Directors may determine.

On January 1, 2011, an additional 509,067 shares were authorized for issuance under the 2005 Plan representing 3.25% of the outstanding shares on that date. As of June 30, 2011 there were 945,013 shares available for future grants under the plans.

Activity under the Plans during the six months ended June 30, 2011 was as follows:

	Number of Shares Outstanding	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
<b>Stock Options</b>				
Outstanding at January 1, 2011	2,787,354	\$ 7.82		
Granted	233,500	\$ 12.24		
Cancelled or forfeited	(12,760)	\$ 5.13		
Exercised	(335,727)	\$ 3.10		
Outstanding at June 30, 2011	2,672,367	\$ 8.81	6.23	\$ 11,238,491
Vested and expected to vest	2,642,872	\$ 8.81	6.19	\$ 11,128,511
Exercisable at June 30, 2011	1,974,075	\$ 8.97	5.36	\$ 7,968,503

**Restricted Stock**

Edgar Filing: AtriCure, Inc. - Form 10-Q

	Number of Shares Outstanding	Weighted Average Grant Date Fair Value
Outstanding at January 1, 2011	371,700	\$ 4.39
Granted	179,500	\$ 11.59
Forfeited	(2,337)	\$ 3.65
Released	(40,202)	\$ 4.96
<b>Outstanding at June 30, 2011</b>	<b>508,661</b>	<b>\$ 6.89</b>

The total intrinsic value of options exercised during the three month periods ended June 30, 2011 and 2010 was \$1,307,743 and \$114,880, respectively. The total intrinsic value of options exercised during the six month periods ended June 30, 2011 and 2010 was \$2,897,685 and \$142,100, respectively. As a result of the Company's tax position, no tax benefit was recognized related to the stock option exercises. For the six month periods ended June 30, 2011 and 2010, respectively, \$1,040,258 and \$34,754 in cash proceeds was included in the Company's Condensed Consolidated Statements of Cash Flows as a result of the exercise of stock options. The total fair value of performance shares vested during the three month periods ended June 30, 2011 and 2010 was \$0 and \$0, respectively. The total fair value of performance shares vested during the six month periods ended June 30, 2011 and 2010 was \$1,243,200 and \$0, respectively. The total fair value of restricted stock vested during the three month periods ended June 30, 2011 and 2010 was \$185,378 and \$174,250, respectively. The total fair value of restricted stock vested during the six month periods ended June 30, 2011 and 2010 was \$490,161 and \$211,834, respectively.

The exercise price per share of each option is equal to the fair market value of the underlying share on the date of grant. The Company issues registered shares of common stock to satisfy stock option exercises and restricted stock grants.



**Table of Contents****ATRICURE, INC. AND SUBSIDIARY****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Unaudited)**

The Company recognized expense related to stock options and restricted stock for the three months ended June 30, 2011 and 2010 of \$663,911 and \$506,478, respectively, and for the six months ended June 30, 2011 and 2010 of \$1,385,269 and \$1,184,345, respectively. As of June 30, 2011 there was \$6,389,491 of unrecognized compensation costs related to non-vested stock option and restricted stock arrangements (\$3,382,911 relating to stock options and \$3,006,580 relating to restricted stock). This cost is expected to be recognized over a weighted average period of 2.5 years for stock options and 1.6 years for restricted stock.

The Company has issued performance shares to certain employees and consultants to incent and reward them for the achievement of specified performance over various service periods. The participants receive awards for a specified number of shares of the Company's common stock at the beginning of the award period, which entitles the participants to the shares at the end of the award period if achievement of the specified metrics and service requirements occurs. During the first quarter of 2011, 111,000 performance shares (gross) were released related to participant's achievement of certain specified metrics. As of June 30, 2011 the Company has the potential to issue 10,000 shares of common stock based upon the participant meeting all of the specified metrics. In accordance with FASB ASC 718, the Company estimates the number of shares to be granted based upon the probability that the performance metric and service period will be achieved. The fair value of the estimated award, based on the market value of the Company's stock on the date of award, is expensed over the award period. The probability of meeting the specified metrics is reviewed quarterly. During the three months ended June 30, 2011 and 2010, the Company recognized expense related to performance shares of \$0 and \$73,155, respectively. During the six months ended June 30, 2011 and 2010, the Company recognized expense related to performance shares of \$0 and \$163,919, respectively. As of June 30, 2011, there was no unrecognized compensation cost related to non-vested share-based compensation arrangements associated with these performance shares.

***Employee Stock Purchase Plan (ESPP)***

During the second quarter of 2008, the Company established its 2008 Employee Stock Purchase Plan ( ESPP ) which is available to eligible employees as defined in the ESPP. Under the ESPP, shares of the Company's common stock may be purchased at a discount (currently 15%) of the lesser of the closing price of the Company's common stock on the first trading day or the last trading day of the offering period. The offering period (currently six months) and the offering price are subject to change. Participants may not purchase more than \$25,000 of the Company's common stock in a calendar year and, effective January 1, 2009, may not purchase more than 1,500 shares during an offering period. Beginning on January 1, 2009 and on the first day of each fiscal year thereafter during the term of the ESPP, the number of shares available for sale under the ESPP shall be increased by the lesser of (i) two percent (2%) of the Company's outstanding shares of common stock as of the close of business on the last business day of the prior calendar year, not to exceed 600,000 shares, or (ii) a lesser amount determined by the Board of Directors. At June 30, 2011, there were 897,157 shares available for future issuance under the ESPP, including 313,272 additional shares approved for issuance by the Company's Board of Directors effective January 1, 2011. Share-based compensation expense with respect to the ESPP was \$66,204 and \$44,018 for the three months ended June 30, 2011 and 2010, respectively, and \$142,084 and \$84,555 for the six months ended June 30, 2011 and 2010, respectively.

***Valuation and Expense Information Under FASB ASC 718***

The following table summarizes share-based compensation expense related to employee share-based compensation under FASB ASC 718 for the three and six months ended June 30, 2011 and 2010. This expense was allocated as follows:

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2011</b>	<b>2010</b>	<b>2011</b>	<b>2010</b>
Cost of revenue	\$ 41,665	\$ 32,643	\$ 81,872	\$ 72,754
Research and development expenses	123,718	129,711	250,048	231,853
Selling, general and administrative expenses	564,732	461,297	1,195,432	1,128,212
Total share-based compensation expense related to employees	\$ 730,115	\$ 623,651	\$ 1,527,353	\$ 1,432,819



**Table of Contents****ATRICURE, INC. AND SUBSIDIARY****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Unaudited)**

In calculating compensation expense, the fair value of the options is estimated on the grant date using the Black-Scholes model including the following assumptions:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2011	2010	2011	2010
Risk free interest rate	2.20%	2.28%	2.48%	2.88%
Expected life of option (years)	6.00	6.25	6.00	6.25
Expected volatility of stock	71.00%	71.00%	71.00%	71.00%
Weighted-average volatility	71.00%	71.00%	71.65%	69.40%
Dividend yield	0.00%	0.00%	0.00%	0.00%

For grants made before December 31, 2010, the Company's estimate of volatility was weighted between the Company's trading history and other companies in the industry. Beginning January 1, 2011, the Company's estimate of volatility is based solely on the Company's trading history. The risk-free interest rate assumption is based upon the U.S. treasury yield curve at the time of grant for the expected option life. The simplified method is utilized in determining the expected life of the option.

The fair value of restricted stock awards is based on the market value of the Company's stock on the date of the awards.

Based on the assumptions noted above, the weighted average estimated fair value per share of the stock options and restricted stock granted for the respective periods was as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2011	2010	2011	2010
Stock options	\$ 9.09	\$ 3.32	\$ 8.01	\$ 3.56
Restricted stock	\$ 14.17	\$ 5.15	\$ 11.59	\$ 5.49

***Non-Employee Stock Compensation***

The Company has issued nonstatutory common stock options to consultants to purchase shares of common stock as a form of compensation for services provided to the Company. Such options vest over a service period ranging from immediately to four years. After January 1, 2006, all stock options to non-employee consultants have a four year vesting period and vest at a rate of 25% on the first anniversary date of the grant and ratably each month thereafter.

The fair value at the date of grant, which is subject to adjustment at each vesting date, was determined using the Black-Scholes model. There were no non-employee stock options granted during the three and six month periods ended June 30, 2011 and 2010. The values attributable to the non-vested portion of the non-employee stock options have been amortized over the service period on a graded vesting method and the vested portion of these stock options was remeasured at each vesting date.

The Company accounts for the options granted to non-employees prior to their vesting date in accordance with ASC 505-50, *Equity-Based Payments to Non-Employees*. Because these options do not contain specific performance provisions, there is no measurement date of fair value until the options vest. Therefore, the fair value of the options granted and outstanding prior to their vesting date is remeasured each reporting period. Stock compensation expense with respect to unvested non-employee stock options totaled \$4,535 and \$3,295, respectively, for the three months ended June 30, 2011 and 2010 and \$10,704 and \$6,161, respectively, for the six months ended June 30, 2011 and 2010.

## Edgar Filing: AtriCure, Inc. - Form 10-Q

Once these non-employee stock options have vested, the awards no longer fall within the scope of ASC 505-50. Because the stock options require settlement by the Company's delivery of registered shares and because the tax withholding provisions in the awards allow the stock options to be partially net-cash settled, these vested stock options are no longer eligible for equity classification and are, thus, accounted for as derivative liabilities under FASB ASC 815 ( Derivatives and Hedging ) until the stock options are ultimately either exercised or forfeited. Accordingly, the vested non-employee stock options are classified as liabilities and remeasured at fair value through earnings at each reporting period. During the three months ended June 30, 2011 and 2010, \$42,703 and \$27,204, respectively, of expense was recorded as a result of the remeasurement of the fair value of these stock options. During the six months ended June 30, 2011 and 2010, \$48,974 and \$27,494, respectively, of expense was recorded as a result of the remeasurement of the fair value of these stock options. As of June 30, 2011 and December 31, 2010, respectively, fully vested stock options to acquire 39,603 and 41,049 shares of common stock held by non-employee consultants remained unexercised and a liability of \$334,990 and \$268,478 was included in accrued liabilities in the Condensed Consolidated Balance Sheets as of June 30, 2011 and December 31, 2010, respectively.

**Table of Contents****ATRICURE, INC. AND SUBSIDIARY****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Unaudited)****10. SEGMENT AND GEOGRAPHIC INFORMATION**

The Company considers reporting segments in accordance with FASB ASC 280, Segment Reporting. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. These devices are developed and marketed to a broad base of medical centers in the United States and internationally. Management considers all such sales to be part of a single segment.

Geographic revenue was as follows:

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2011</b>	<b>2010</b>	<b>2011</b>	<b>2010</b>
United States	\$ 12,661,752	\$ 11,845,297	\$ 24,784,295	\$ 22,895,471
International	4,117,811	2,347,015	7,632,349	5,248,641
<b>Total</b>	<b>\$ 16,779,563</b>	<b>\$ 14,192,312</b>	<b>\$ 32,416,644</b>	<b>\$ 28,144,112</b>

Substantially all of the Company's long-lived assets are located in the United States.

**11. SUBSEQUENT EVENT**

On July 15, 2011, the Company was awarded a \$1,000,000 grant through the Ohio Third Frontier Biomedical Program, a program designed to accelerate the development and growth of the biomedical industry and supply chains in the state of Ohio. The program provides direct financial support to organizations seeking to commercialize new products, adapt or modify existing devices, diagnostics or components, address technical and commercialization barriers or demonstrate market readiness. The Company will utilize the grant to develop and commercialize a minimally invasive left atrial appendage exclusion device. The grant will be earned as qualifying expenditures are made.

## **Table of Contents**

### **Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the accompanying Condensed Consolidated Financial Statements and notes thereto contained in Item 1 of Part I of this Form 10-Q and our audited financial statements and notes thereto as of and for the year ended December 31, 2010 included in our Form 10-K filed with the Securities and Exchange Commission (SEC) to provide an understanding of our results of operations, financial condition and cash flows.

### **Forward-Looking Statements**

This Form 10-Q, including the sections titled Management's Discussion and Analysis of Financial Condition and Results of Operations and Risk Factors, contains forward-looking statements regarding our future performance. All forward-looking information is inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors, including those set forth under Risk Factors and elsewhere in this quarterly report on Form 10-Q, and in our annual report on Form 10-K for the year ended December 31, 2010. Forward-looking statements convey our current expectations or forecasts of future events. All statements contained in this Form 10-Q other than statements of historical fact are forward-looking statements. Forward-looking statements include statements regarding our future financial position, business strategy, budgets, projected costs, plans and objectives of management for future operations. The words may, continue, estimate, intend, plan, will, believe, project, expect, anticipate and other similar expressions may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. With respect to the forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. These forward-looking statements speak only as of the date of this Form 10-Q. Unless required by law, we undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise.

### **Overview**

We are a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue and systems designed to exclude the left atrial appendage. We have two product lines for the ablation of cardiac tissue. Our primary product line for the ablation of cardiac tissue, which accounts for a majority of our revenue, is our Isolator<sup>®</sup> Synergy bipolar ablation clamp system, or Isolator system, and related radiofrequency ablation devices. We also offer a cryoablation product line, which features reusable and disposable cryoablation devices. Additionally, we offer the AtriClip<sup>®</sup> Gillinov-Cosgrove Left Atrial Appendage System, or AtriClip system, which is designed to safely and effectively exclude the left atrial appendage.

Cardiothoracic surgeons have adopted our Isolator and cryoablation systems to treat atrial fibrillation, or AF, in an estimated 100,000 patients since January 2003, and we believe that we are currently the market leader in the surgical treatment of AF. Our products are utilized by cardiothoracic surgeons during concomitant cardiac surgical procedures and also during sole-therapy minimally invasive cardiac ablation procedures. During a concomitant open procedure, the surgeon ablates cardiac tissue and/or treats the left atrial appendage, secondary, or concomitant, to a primary cardiac procedure such as a valve or coronary bypass. Additionally, cardiothoracic surgeons have adopted our products as a standard treatment alternative for AF patients who may be candidates for sole-therapy minimally invasive surgical procedures. To date, none of our products have been approved or cleared by the Food and Drug Administration, or FDA, for the treatment of AF or the reduction in stroke. However, we are conducting clinical trials to investigate the safety and effectiveness of our products for the treatment of AF. We anticipate that substantially all of our revenue for the foreseeable future will relate to products we currently sell, or are in the process of developing, which surgeons generally use to ablate cardiac tissue for the treatment of AF or for the exclusion of the left atrial appendage.

### **Recent Developments**

During the third quarter of 2010, our DEEP AF clinical trial was approved by the FDA. DEEP AF is a feasibility trial designed to evaluate the safety and effectiveness of our minimally invasive products with catheter mapping and ablation technologies for the treatment of patients with persistent or long-standing persistent AF. During the first quarter of 2011, the trial was modified to include the use of the AtriClip system to exclude the left atrial appendage. The 30-patient trial is being conducted at six U.S. medical centers. Enrollment in the trial was initiated in December 2010 and is anticipated to be completed during 2011. To date, 17 patients have been enrolled in the trial.

In December 2010 we submitted our final clinical module to the FDA, including the supplementary data, in support of a PMA approval. During February 2011, we were notified by the FDA that our PMA achieved fileable status and received expedited review status. In March 2011, we received a major deficiency letter related to the ABLATE PMA which highlights items on which the FDA requests clarification, and, in June 2011, we responded to these questions. Additionally, during February 2011, the FDA began its PMA manufacturing review, which resulted in the issuance of a Form FDA 483, Inspectional Observations, which outlined



**Table of Contents**

deficiencies observed by the FDA inspectors. We responded to the observations and have taken corrective actions where appropriate. An approval of the ABLATE PMA would allow us to market our Isolator system for the treatment of patients with permanent AF (as defined in the trial protocol) during open-heart procedures.

In April 2011 we received clearance from the FDA for our Isolator Synergy Access device for the ablation of cardiac tissue during surgery. We initiated a full commercial release of Isolator Synergy Access in July 2011.

In May 2011 we received clearance from the FDA for our initial Cryo Module System, or *cryoICE* BOX, for the cryosurgical treatment of cardiac arrhythmias. We received CE Mark for the *cryoICE* BOX in February 2011. We initiated a commercial release of *cryoICE* BOX in Europe in June 2011. During July 2011 we submitted a supplemental 510(k) to the FDA for enhancements made to the *cryoICE* BOX, and we anticipate full commercial release in the U.S. by the end of the third quarter of 2011.

In June 2011 we began planning for the discontinuance of the manufacturing of our Coolrail and Cryo1 devices, which have been replaced with our Multifunctional Linear Pen and *cryoICE* devices, respectively.

In July 2011 we were awarded a \$1 million grant from the Ohio Third Frontier Commission, a technology-based economic development initiative dedicated to supporting existing industries that are transforming themselves with new globally competitive products and fostering the formation and attraction of new companies in emerging industry sectors in the state of Ohio. The grant will be used to develop and commercialize a left atrial appendage exclusion device for use in minimally invasive standalone procedures.

On August 2, 2011 we filed an IDE with the FDA for a new feasibility trial. The 30-patient trial is designed to study the thoracoscopic deployment of the AtriClip system for the exclusion of the left atrial appendage for stroke prevention in patients with non-valvular AF who are not indicated for anticoagulation therapy.

**Results of Operations*****Three months ended June 30, 2011 compared to three months ended June 30, 2010***

The following table sets forth, for the periods indicated, our results of operations expressed as dollar amounts and as percentages of total revenue:

	Three Months Ended June 30,			
	2011	% of Revenues	2010	% of Revenues
	Amount	(dollars in thousands)	Amount	Revenues
Revenue	\$ 16,780	100.0%	\$ 14,192	100.0%
Cost of revenue	4,502	26.8%	2,964	20.9%
Gross profit	12,277	73.2%	11,229	79.1%
Operating expenses:				
Research and development expenses	2,879	17.2%	2,422	17.1%
Selling, general and administrative expenses	10,170	60.6%	9,239	65.1%
Total operating expenses	13,049	77.8%	11,661	82.2%
Loss from operations	(771)	(4.6%)	(433)	(3.1%)
Other income (expense):				
Interest expense	(172)	(1.0%)	(215)	(1.5%)
Interest income	4	0.0%	6	0.0%
Other	2	0.0%	(123)	(0.9%)
Total other expense	(166)	(1.0%)	(332)	(2.3%)



Edgar Filing: AtriCure, Inc. - Form 10-Q

Loss before income tax expense	(937)	(5.6%)	(764)	(5.4%)
Income tax expense	(9)	(0.1%)		
Net loss	\$ (947)	(5.6%)	\$ (765)	(5.4%)

---

**Table of Contents**

**Revenue.** Total revenue increased 18.2% (16.1% on a constant currency basis), from \$14.2 million for the three months ended June 30, 2010 to \$16.8 million for the three months ended June 30, 2011. Revenue from sales to customers in the United States increased \$0.8 million, or 6.9%, and revenue from sales to international customers increased \$1.8 million, or 75.4%. The increase in sales to customers in the United States was primarily due to increased sales of the AtriClip system of \$1.2 million, a new product offering that was released at the end of the second quarter of 2010. This increase was partially offset by a reduction in revenue from ablation-related products, which we believe was due primarily to a reduction in minimally invasive standalone cardiac ablation procedures. The increase in international revenue was primarily due to:

an increase in sales in Europe, primarily in our direct markets. The direct market growth included the benefit of the third quarter 2010 transition of the Benelux region to a direct market, as we did not have revenue from the distributor during the second quarter of 2010, as well as an increase in average selling prices resulting from going direct;

an increase in sales in Asia; and

foreign currency exchange fluctuations. International revenue growth on a constant currency basis was 62.8% as compared to the reported 75.4%.

**Cost of revenue and gross margin.** Cost of revenue increased \$1.5 million, from \$3.0 million for the three months ended June 30, 2010 to \$4.5 million for the three months ended June 30, 2011. The increase in cost of revenue was primarily due to an increase in revenue and an increase in product cost primarily due to an increased mix of capital equipment sales, an increase in resources being dedicated to manufacturing related activities and the impact of an inventory reserve associated with the planned discontinuance of the Coolrail and Cryo1 products. As a percentage of revenue, cost of revenue increased from 20.9% for the three months ended June 30, 2010 to 26.8% for the three months ended June 30, 2011. Gross margin for the three months ended June 30, 2011 and 2010 was 73.2% and 79.1%, respectively. The decrease in gross margin was primarily due to:

an increased mix of revenue from the AtriClip system, which has a lower gross margin than other disposable products;

expenses associated with the planned discontinuance of the manufacturing of our Coolrail and Cryo1 devices, which have been replaced with our Multifunctional Linear Pen and cryoICE devices, respectively;

an increase in capital equipment sales; and

an increased mix of international sales.

**Research and development expenses.** Research and development expenses increased \$0.5 million, from \$2.4 million for the three months ended June 30, 2010 to \$2.9 million for the three months ended June 30, 2011. As a percentage of revenue, research and development expenses increased from 17.1% for the three months ended June 30, 2010 to 17.2% for the three months ended June 30, 2011. The increase in expense was primarily due to a \$0.4 million increase in clinical activities and clinical trial enrollment related expenses.

**Selling, general and administrative expenses.** Selling, general and administrative expenses increased \$0.9 million, or 10.1%, from \$9.2 million for the three months ended June 30, 2010 to \$10.2 million for the three months ended June 30, 2011. The increase was primarily due to a \$0.8 million increase in sales and marketing expenditures, driven by a \$0.7 million increase in headcount-related and travel expenses driven by an increase in average worldwide sales and marketing headcount of 9 sales and marketing personnel in support of our growth initiatives.

**Net interest expense.** Net interest expense was \$0.2 million for the three months ended June 30, 2011 and 2010. Net interest expense primarily represents interest expense related to amounts outstanding on our term loan, amortization of the debt discount related to the warrants issued in conjunction with the term loan and amortization of debt issuance costs.

## Edgar Filing: AtriCure, Inc. - Form 10-Q

**Other income (expense).** Other income (expense) consists primarily of foreign currency transaction gains/losses, grant income, and non-employee option expense/income related to the fair market value change for fully vested options outstanding for consultants, which are accounted for as free-standing derivatives. Other income (expense) for the three months ended June 30, 2011 and 2010 totaled \$1,614 and (\$122,950), respectively. For the three months ended June 30, 2011 and 2010, foreign currency transaction gains (losses) were \$40,257 and (\$95,745), respectively. Grant income for the three months ended June 30, 2011 and 2010 was \$4,060 and \$0, respectively. Other income (expense) for the three months ended June 30, 2011 and 2010 included expense of \$42,703 and \$27,204, respectively, associated with an increase in value of certain non-employee stock options.

**Table of Contents****Six months ended June 30, 2011 compared to six months ended June 30, 2010**

The following table sets forth, for the periods indicated, our results of operations expressed as dollar amounts and as percentages of total revenue:

	Six Months Ended June 30, 2011		2010	
	Amount	% of Revenues (dollars in thousands)	Amount	% of Revenues
Revenue	\$ 32,417	100.0%	\$ 28,144	100.0%
Cost of revenue	8,246	25.4%	6,236	22.2%
Gross profit	24,170	74.6%	21,908	77.8%
Operating expenses:				
Research and development expenses	5,823	18.0%	5,080	18.1%
Selling, general and administrative expenses	20,192	62.3%	18,951	67.3%
Total operating expenses	26,016	80.3%	24,031	85.4%
Loss from operations	(1,845)	(5.7%)	(2,123)	(7.5%)
Other income (expense):				
Interest expense	(481)	(1.5%)	(478)	(1.7%)
Interest income	9		13	
Other	112	0.4%	(187)	(0.7%)
Other expense	(361)	(1.1%)	(652)	(3.2%)
Loss before income tax (expense) benefit	(2,206)	(6.8%)	(2,776)	(9.9%)
Income tax (expense) benefit	(14)		2	
Net loss	\$ (2,220)	(6.8%)	\$ (2,774)	(9.9%)

**Revenue.** Total revenue increased 15.2% (14.1% on a constant currency basis), from \$28.1 million for the six months ended June 30, 2010 to \$32.4 million for the six months ended June 30, 2011. Revenue from sales to customers in the United States increased \$1.9 million, or 8.3%, and revenue from sales to international customers increased \$2.4 million, or 45.4% (39.8% on a constant currency basis). The increase in sales to customers in the United States was primarily due to increased sales of the AtriClip system of \$2.7 million, a new product offering that was released at the end of the second quarter of 2010. This increase was partially offset by a reduction in revenue from ablation-related products, which we believe was primarily due to a reduction in minimally invasive standalone cardiac ablation procedures. The increase in international revenue was primarily due to:

an increase in sales in Europe, primarily in our direct markets. The direct market growth included the benefit of the third quarter 2010 transition of the Benelux region to a direct market, as we did not have revenue from the distributor during the second quarter of 2010, as well as an increase in average selling prices resulting from going direct;

an increase in sales in Asia; and

foreign currency exchange fluctuations. International revenue growth on a constant currency basis was 39.8% as compared to the reported 45.4%.

## Edgar Filing: AtriCure, Inc. - Form 10-Q

**Cost of revenue and gross margin.** Cost of revenue increased from \$6.2 million for the six months ended June 30, 2010 to \$8.2 million for the six months ended June 30, 2011. The increase in cost of revenue was primarily due to an increase in revenue, an increased mix of capital equipment sales and costs associated with planning to discontinue the manufacturing of our Coolrail and Cryo1 devices. As a percentage of revenue, cost of revenue increased from 22.2% for the six months ended June 30, 2010 to 25.4% for the six months ended June 30, 2011. Gross margin for the six months ended June 30, 2011 and 2010 was 74.6% and 77.8%, respectively. The decrease in gross margin was primarily due to:

an increased mix of revenue from capital equipment sales;

an increased mix of AtriClip sales, which has a lower gross margin than our other single-use products;

costs associated with planning to discontinue the manufacturing of our Coolrail and Cryo1 devices, which have been replaced with our Multifunctional Linear Pen and *cryoICE* devices, respectively; and

an increased mix of international sales.

---

**Table of Contents**

**Research and development expenses.** Research and development expenses increased \$0.7 million, from \$5.1 million for the six months ended June 30, 2010 to \$5.8 million for the six months ended June 30, 2011. As a percentage of revenue, research and development expenses decreased from 18.1% for the six months ended June 30, 2010 to 18.0% for the six months ended June 30, 2011. The increase in expense was primarily due to a \$0.8 million increase in clinical and regulatory related expenses due to a \$0.3 million increase in clinical trial related enrollment expenses for DEEP AF and ABLATE AF and a \$0.3 million increase in consulting expenses due to an increase in clinical and regulatory activities.

**Selling, general and administrative expenses.** Selling, general and administrative expenses increased \$1.2 million, or 6.5%, from \$19.0 million for the six months ended June 30, 2010 to \$20.2 million for the six months ended June 30, 2011. The increase was primarily attributable to a \$1.0 million increase in sales and marketing expenses, due primarily to an increase of \$1.3 million in headcount-related and travel expenses driven by an increase in average worldwide sales and marketing headcount of 9 sales and marketing personnel in support of our growth initiatives and a \$0.3 million decrease in physician consulting payments due to reduced training activities in the United States.

**Net interest expense.** Net interest expense was \$0.5 million for the six months ended June 30, 2011 and 2010. Net interest expense primarily represents interest expense related to amounts outstanding on our term loan, amortization of the debt discount related to the warrants issued in conjunction with the term loan and amortization of debt issuance costs.

**Other income (expense).** Other income (expense) consists primarily of foreign currency transaction gains/losses, grant income, and non-employee option expense/income related to the fair market value change for fully vested options outstanding for consultants, which are accounted for as free-standing derivatives. Other income (expense) for the six months ended June 30, 2011 and 2010 totaled \$111,527 and (\$187,446), respectively. For the six months ended June 30, 2011 and 2010, foreign currency transaction gains (losses) were \$136,288 and (\$159,952), respectively. Grant income for the six months ended June 30, 2011 and 2010 was \$24,213 and \$0, respectively. Other income (expense) for the six months ended June 30, 2011 and 2010 included expense of \$48,974 and \$27,494, respectively, associated with an increase in value of certain non-employee stock options.

**Liquidity and Capital Resources**

As of June 30, 2011, we had cash, cash equivalents and investments of \$16.4 million and short-term and long-term debt of \$7.2 million, resulting in a net cash position of \$9.2 million. We had unused borrowing capacity of approximately \$8.2 million under our revolving credit facility. We had net working capital of \$22.4 million and an accumulated deficit of \$100.0 million as of June 30, 2011.

**Cash flows used in operating activities.** Net cash used in operating activities for the six months ended June 30, 2011 was \$0.5 million. The primary uses of cash were as follows:

The net loss of \$2.2 million, offset by \$2.9 million of non-cash expenses, including \$1.5 million in share-based compensation, \$1.1 million in depreciation and amortization and \$0.2 million for the write-off of deferred financing costs and discount on long-term debt; and

A net use of cash related to changes in operating assets and liabilities of \$1.2 million, due primarily to the following:

an increase in accounts receivable of \$0.5 million, due primarily to an increase in amounts due from a distributor of \$1.1 million who has increased revenue and for who we recently provided extended payment terms as compared to our other distributors; and

a \$0.8 million reduction in accrued liabilities primarily due to the payment of 2010 related compensation.

**Cash flows used in investing activities.** Net cash used in investing activities was \$4.5 million for the six months ended June 30, 2011. The primary investing cash activities were as follows:

## Edgar Filing: AtriCure, Inc. - Form 10-Q

a use of cash of \$0.6 million related to the purchase of equipment, which consisted primarily of loans of our generators (i.e. our ablation and sensing unit) to our customers;

proceeds from the sale of equipment of \$0.1 million; and

net investment purchases of \$4.0 million.

**Cash flows provided by financing activities.** For the six months ended June 30, 2011, net cash provided by financing activities was \$5.0 million, which was primarily due to net proceeds from the modified SVB term loan borrowing of \$5.0 million, partially offset by debt repayments of \$0.8 million, and proceeds from stock option exercises of \$1.0 million, partially offset by shares repurchased for payment of taxes on stock awards of \$0.5 million.

**Credit facility.** On May 1, 2009, we entered into a Loan and Security Agreement (the Agreement) with Silicon Valley Bank (SVB) that provided for a term loan and a revolving credit facility under which we could borrow a maximum of \$10.0 million. We could borrow up to \$10.0 million under the revolving loan facility with the availability subject to a borrowing base formula. On May 1, 2009, we borrowed the maximum amount of \$6.5 million under the term loan. In connection with the term loan, SVB received

**Table of Contents**

a warrant to purchase 371,732 shares of our common stock at \$1.224 per share, exercisable for a term of ten years (the Warrant ). The Warrant was immediately exercisable and was exercised via a net share settlement exercise on October 6, 2009, resulting in the issuance of 276,143 shares of our common stock. The Agreement also includes up to a \$1.0 million sublimit for stand-by letters of credit.

On November 4, 2009, effective September 30, 2009, we entered into a Consent, Waiver and First Loan Modification Agreement with SVB, which amended, among other things, the financial covenants in the Agreement. On March 26, 2010, we entered into a Waiver and Second Loan Modification Agreement with SVB, which amended, among other things, the financial covenants in the Agreement and waived a compliance violation which occurred during February 2010.

On September 13, 2010, we entered into an Amended and Restated Loan and Security Agreement with SVB and an Export-Import Bank Loan and Security Agreement. This amendment increased our credit facility from \$10.0 million to approximately \$14.0 million. The amendment also increased our borrowing capacity under the revolving loan facility by expanding total availability, eliminating a term loan reserve requirement, adding a sublimit secured by certain of our foreign accounts receivable and inventory up to \$2.0 million and adding incremental borrowing availability secured by a portion of our domestic inventory. Interest on the term loan portion accrued at a rate of 10.0% per year, and interest on the revolving loan would accrue at a fluctuating rate equal to SVB's announced prime rate of interest, subject to a floor of 4.0%, plus between 1.0% and 2.0%, depending on our Adjusted Quick Ratio (as defined in the Agreement). Principal on the term loan was being amortized over 36 months of equal principal payments of approximately \$181,000, plus applicable interest. The Agreement was to mature on April 30, 2012 and was secured by all of our assets, including intellectual property.

On March 15, 2011, we entered into a First Loan Modification Agreement (the Loan Modification Agreement ) and an Export-Import Bank First Loan Modification Agreement (the Ex-Im Agreement and, collectively with the Loan Modification Agreement, the Modification Agreements ) which set forth certain amendments to our credit facility with SVB. The Loan Modification Agreement provided for a new \$7.5 million term loan. The proceeds from the term loan were used to repay the existing SVB term loan of \$2.5 million. The balance was invested in short-term investments. The new term loan has a five-year term, and principal payments in the amount of \$125,000, together with accrued interest, are due and payable monthly. The modified term loan accrues interest at a fixed rate of 6.75%.

The Modification Agreements also provide for a two-year extension of the maturity date of the existing revolving credit facility from April 30, 2012 to April 30, 2014. The applicable borrowing rate was reduced to 0.25% to 0.75% above the prime rate. The maximum borrowing amount under the revolving facility remained at \$10.0 million.

The Agreement, as amended, contains covenants that include, among others, covenants that limit our ability to dispose of assets, enter into mergers or acquisitions, incur indebtedness, incur liens, pay dividends or make distributions on our capital stock, make investments or loans, and enter into certain affiliate transactions, in each case subject to customary exceptions for a credit facility of this size and type. Additional covenants apply when we have outstanding borrowings under the revolving loan facility or when we achieve specific covenant milestones. Financial covenants under the credit facility, as amended, include a minimum EBITDA, a limitation on capital expenditures, and a minimum adjusted quick ratio. Further, a minimum fixed charge ratio applies when we achieve specific covenant milestones. The occurrence of an event of default could result in an increase to the applicable interest rate by 3.0%, an acceleration of all obligations under the Agreement, an obligation to repay all obligations in full, and a right by SVB to exercise all remedies available to it under the Agreement and related agreements including the Guaranty and Security Agreement. As of and for the period ended June 30, 2011, we were in compliance with all of the financial covenants of our amended and modified credit facility. In addition, if the guarantee by the Export-Import Bank of the United States ceases to be in full force and effect, we must repay all loans under the Export-Import agreement.

As of June 30, 2011, we had no borrowings under the revolving credit facility and had borrowing availability of approximately \$8.2 million. Also, as of June 30, 2011, \$7.1 million was outstanding under the term loan, which included \$1.5 million classified as current maturities of long-term debt.

The Warrant that was issued with the initial SVB Agreement had been recorded as a discount on long-term debt at its fair value and was being amortized over the term of the loan. Accelerated amortization expense of \$78,873 was recorded in March 2011 due to the credit facility modification. No amortization expense related to the Warrant was recorded for the three months ended June 30, 2011.

The effective interest rate on borrowings under the modified term loan, including debt issuance costs, is 8.0%. We had an outstanding letter of credit of \$250,000 issued to our corporate credit card program provider which was due to expire on July 31, 2011. This letter of credit was cancelled in June 2011, and no letters of credit were outstanding at June 30, 2011.

**Uses of liquidity and capital resources.** Our future capital requirements depend on a number of factors, including possible acquisitions and joint ventures, the rate of market acceptance of our current and future products, the resources we devote to developing and supporting our



## Edgar Filing: AtriCure, Inc. - Form 10-Q

products, future expenses to expand and support our sales and marketing efforts, costs relating to changes in regulatory policies or laws that affect our operations and costs of filing, costs associated with clinical trials and securing regulatory approval for new products, and costs associated with prosecuting, defending and enforcing our intellectual property rights. Global economic turmoil may adversely impact our revenue, access to the capital markets or future demand for our products.

---

**Table of Contents**

We believe that our current cash, cash equivalents and investments, along with the cash we expect to generate or use for operations or access via our revolving credit facility, will be sufficient to meet our anticipated cash needs for working capital and capital expenditures for at least the next twelve months. Significant cash needs over the next twelve months include debt service of approximately \$1.9 million (\$125,000 per month plus interest) on our outstanding term loan, payments under our settlement agreement with the DOJ and Relator of \$0.7 million, and payments under the distributor termination and consulting agreement of approximately \$0.3 million. If our sources of cash are insufficient to satisfy our liquidity requirements, we may seek to sell additional equity or debt securities or obtain a revised or additional credit facility. The sale of additional equity or convertible debt securities could result in dilution to our stockholders. If additional funds are raised through the issuance of debt securities, these securities could have rights senior to those associated with our common stock and could contain covenants that would restrict our operations. Additional financing may not be available at all, or in amounts or terms acceptable to us. If we are unable to obtain this additional financing, we may be required to reduce the scope of our planned research and development, clinical activities and selling and marketing efforts.

**Off-Balance-Sheet Arrangements**

As of June 30, 2011, we had operating lease agreements not recorded on the Condensed Consolidated Balance Sheet. Operating leases are utilized in the normal course of business.

**Seasonality**

During the first quarter, we have historically experienced an increase in our operating expenses and operating loss due to higher selling, general and administrative expenses related primarily to our participation in and attendance at large industry events. During the third quarter, we typically experience a decline in revenue that we attribute primarily to the elective nature of the procedures in which our products are used, which we believe arises from fewer people choosing to undergo elective procedures during the summer months.

**Critical Accounting Policies and Estimates**

Our discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States ( GAAP ). The preparation of financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, revenue and expenses, and disclosures of contingent assets and liabilities at the date of the financial statements. On a periodic basis, we evaluate our estimates, including those related to sales returns and allowances, accounts receivable, inventories and share-based compensation. We use authoritative pronouncements, historical experience and other assumptions as the basis for making estimates. Actual results could differ from those estimates under different assumptions or conditions. Our Annual Report on Form 10-K for the fiscal year ended December 31, 2010 includes additional information about the Company, our operations, our financial position, our critical accounting policies and accounting estimates and should be read in conjunction with this Quarterly Report.

**Recent Accounting Pronouncements**

See Note 2 in the Notes to the Condensed Consolidated Financial Statements for a discussion of recent accounting pronouncements.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

As of June 30, 2011, there were no material changes to the information provided under Item 7A-Quantitative and Qualitative Disclosures About Market Risk in the Company's Form 10-K for the year ended December 31, 2010.

**Item 4. Controls and Procedures  
Disclosure Controls and Procedures**

We have evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13(a)-15(e) and 15(d)-15(e) of the Securities Exchange Act of 1934 (the Exchange Act ), as of the end of the period covered by this report. Our management, including the Chief Executive Officer and Chief Financial Officer, supervised and participated in the evaluation. Based on the evaluation, we concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective in providing reasonable

## Edgar Filing: AtriCure, Inc. - Form 10-Q

assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's forms and rules, and the material information relating to the Company is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

## **Table of Contents**

Control systems, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that control objectives are met. Because of inherent limitations in all control systems, no evaluation of controls can provide assurance that all control issues and instances of fraud, if any, within a company will be detected. Additionally, controls can be circumvented by individuals, by collusion of two or more people, or by management override. Over time, controls can become inadequate because of changes in conditions or the degree of compliance may deteriorate. Further, the design of any system of controls is based in part upon assumptions about the likelihood of future events. There can be no assurance that any design will succeed in achieving its stated goals under all future conditions. Because of the inherent limitations in any cost-effective control system, misstatements due to errors or fraud may occur and not be detected.

### **Changes in Internal Control Over Financial Reporting**

There were no changes in our internal control over financial reporting that occurred during the three months ended June 30, 2011 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## **PART II. OTHER INFORMATION**

### **Item 1. Legal Proceedings**

Information with respect to legal proceedings can be found under the heading "Legal" in Note 7, "Commitments and Contingencies" to the Condensed Consolidated Financial Statements in Part I, Item 1 of this Quarterly Report on Form 10-Q, and is incorporated herein by reference.

### **Item 1A. Risk Factors**

In addition to the other information set forth in this report, careful consideration should be given to the factors discussed in Part I, Item 1A. Risk Factors in our Form 10-K for the year ended December 31, 2010, all of which could materially affect our business, financial condition or future results. The risks described are not the only risks facing us. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial, also may adversely affect our business, financial condition and/or operating results. There have been no material changes with respect to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2010.

**Table of Contents****Item 6. Exhibits**

<b>Exhibit</b>	
<b>No.</b>	<b>Description</b>
31.1	Rule 13a-14(a) Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Rule 13a-14(a) Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification pursuant to 18 U.S.C. Section 1350 by the Chief Executive Officer, as adopted, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification pursuant to 18 U.S.C. Section 1350 by the Chief Financial Officer, as adopted, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document

\* XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AtriCure, Inc.  
(REGISTRANT)

Date: August 5, 2011

/s/ David J. Drachman  
**David J. Drachman**  
**President and Chief Executive Officer**

**(Principal Executive Officer)**

Date: August 5, 2011

/s/ Julie A. Piton  
**Julie A. Piton**  
**Vice President, Finance and Administration and Chief Financial Officer**

**(Principal Financial and Accounting Officer)**

**Table of Contents****EXHIBIT INDEX**

<b>Exhibit</b>	
<b>No.</b>	<b>Description</b>
31.1	Rule 13a-14(a) Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Rule 13a-14(a) Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification pursuant to 18 U.S.C. Section 1350 by the Chief Executive Officer, as adopted, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification pursuant to 18 U.S.C. Section 1350 by the Chief Financial Officer, as adopted, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document

\* XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.